1 line
2.8 KiB
JSON
1 line
2.8 KiB
JSON
{"acne": 3.31, "acquired gene mutation": 19.54, "aplastic anaemia": 2.66, "blood creatine phosphokinase increased": 2.62, "blood sodium decreased": 2.22, "brain neoplasm": 6.27, "brain oedema": 3.44, "carcinoembryonic antigen increased": 51.67, "cardiac dysfunction": 12.68, "cardiac failure": 8.92, "cardiac failure acute": 5.85, "cardiac failure chronic": 3.81, "cardiac failure congestive": 2.46, "cardiac tamponade": 5.98, "cardiomyopathy": 6.54, "cardiotoxicity": 5.42, "cerebral infarction": 3.15, "cutaneous vasculitis": 3.69, "decreased appetite": 3.38, "dermatitis": 3.81, "dermatitis acneiform": 23.3, "diarrhoea": 3.36, "dilated cardiomyopathy": 3.63, "disease progression": 2.66, "drug eruption": 2.76, "drug resistance": 6.28, "dry eye": 2.11, "dry skin": 9.75, "egfr gene mutation": 58.3, "ejection fraction decreased": 13.0, "electrocardiogram qt prolonged": 16.88, "erythema multiforme": 5.97, "feeding disorder": 3.29, "femur fracture": 2.64, "fracture": 4.01, "general physical health deterioration": 2.26, "haematotoxicity": 3.48, "haemoptysis": 2.71, "heart failure with reduced ejection fraction": 34.53, "hepatic function abnormal": 2.67, "hypophagia": 2.57, "interstitial lung disease": 51.33, "keratitis": 18.23, "liver disorder": 3.77, "long qt syndrome": 14.35, "lung disorder": 9.92, "lung infiltration": 2.22, "lung neoplasm maligt": 3.15, "lung opacity": 27.5, "lymphangiosis carcinomatosa": 65.68, "maligt neoplasm progression": 24.06, "maligt pleural effusion": 20.03, "metastases to bone": 19.55, "metastases to central nervous system": 53.01, "metastases to liver": 8.82, "metastases to lung": 8.11, "metastases to lymph nodes": 8.67, "metastases to meninges": 85.76, "metastases to pleura": 31.86, "metastases to spine": 18.8, "metastasis": 21.53, "mouth ulceration": 2.19, "mucosal disorder": 7.2, "mucosal inflammation": 4.02, "myelosuppression": 3.03, "nail bed inflammation": 100.59, "nail disorder": 32.79, "neoplasm progression": 2.64, "neutrophil count decreased": 2.39, "no adverse event": 2.42, "non-small cell lung cancer": 8.53, "onychoclasis": 38.3, "palmar-plantar erythrodysaesthesia syndrome": 2.48, "paronychia": 150.83, "pericardial effusion": 3.85, "platelet count decreased": 4.73, "pleural effusion": 10.57, "pneumocystis jirovecii pneumonia": 2.32, "pneumonia bacterial": 7.74, "pneumonitis": 41.29, "pneumothorax": 7.0, "pulmonary alveolar haemorrhage": 4.26, "pulmonary embolism": 2.63, "pulmonary mass": 3.16, "pulmonary oedema": 3.03, "pulmonary toxicity": 73.14, "pustule": 2.62, "rash": 2.27, "respiratory failure": 3.25, "sars-cov-2 test negative": 12.58, "skin disorder": 5.17, "skin fissures": 17.19, "skin toxicity": 9.44, "skin ulcer": 2.37, "small cell lung cancer": 21.71, "stomatitis": 6.61, "taste disorder": 3.12, "thrombocytopenia": 4.4, "tumour marker increased": 12.73, "white blood cell count decreased": 2.17} |